PMID- 32619330
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 2157-6580 (Electronic)
IS  - 2157-6564 (Print)
IS  - 2157-6564 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct
TI  - Umbilical cord blood: The promise and the uncertainty.
PG  - 1153-1162
LID - 10.1002/sctm.19-0288 [doi]
AB  - Unfortunately, many patients referred for hematopoietic cell transplant will not 
      have a fully matched related donor, and finding matched unrelated donors through 
      the registry may be difficult, especially if the recipient is not of Northern 
      European descent [N Engl J Med 2014;371:339-348]. Umbilical cord blood (UCB) has 
      been an available graft source for hematopoietic cell transplant for more than 
      30 years, since the first UCB transplant was performed in the late 1980s [N Engl 
      J Med 1989;321:1174-1178]. UCB is readily available, has low immunogenicity, and 
      does not require as strict of human leukocyte antigen (HLA) matching compared to 
      other graft sources [N Engl J Med 2004;351:2265-2275]. According to data from the 
      Center for International Blood and Marrow Transplant Research (CIBMTR), an 
      estimated 500 patients in the US will have received a UCB transplant in 2018. 
      Since 2014, haploidentical transplants have surpassed UCB transplants performed 
      in the United States (CIBMTR Summary Slides, 2018, available at 
      https://www.cibmtr.org). Increased use of haploidentical transplants has brought 
      to light concerns about UCB transplants, including delayed engraftment and graft 
      failure, increased nonrelapse mortality, increased infection risk, and UCB 
      acquisition costs [Lancet Oncol 2010;11:653-660; Biol Blood Marrow Transplant 
      2019;1456-1464]. These concerns will need to be addressed for UCB to remain a 
      viable option as a graft source for hematopoietic cell transplant. Other 
      promising therapeutic benefits for UCB, in addition to hematopoietic cell 
      transplant, is its use in regenerative medicine and immune modulation, which is 
      currently being evaluated in ongoing clinical trials.
CI  - (c) 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley 
      Periodicals, Inc. on behalf of AlphaMed Press.
FAU - Kindwall-Keller, Tamila L
AU  - Kindwall-Keller TL
AD  - Division of Hematology/Oncology, University of Virginia, Charlottesville, 
      Virginia, USA.
FAU - Ballen, Karen K
AU  - Ballen KK
AD  - Division of Hematology/Oncology, University of Virginia, Charlottesville, 
      Virginia, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200703
PL  - England
TA  - Stem Cells Transl Med
JT  - Stem cells translational medicine
JID - 101578022
SB  - IM
CIN - Stem Cells Transl Med. 2020 Oct;9(10):1118-1120. PMID: 32619325
MH  - Cord Blood Stem Cell Transplantation/*methods
MH  - Female
MH  - Humans
MH  - Male
PMC - PMC7519764
OTO - NOTNLM
OT  - hematologic malignancies
OT  - hematopoietic cell transplant
OT  - umbilical cord blood
COIS- The authors declared no potential conflicts of interest.
EDAT- 2020/07/04 06:00
MHDA- 2021/09/02 06:00
PMCR- 2020/07/03
CRDT- 2020/07/04 06:00
PHST- 2019/09/05 00:00 [received]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/10 00:00 [accepted]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/03 00:00 [pmc-release]
AID - SCT312750 [pii]
AID - 10.1002/sctm.19-0288 [doi]
PST - ppublish
SO  - Stem Cells Transl Med. 2020 Oct;9(10):1153-1162. doi: 10.1002/sctm.19-0288. Epub 
      2020 Jul 3.